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The current study was undertaken to characterize the RRDR rpoB gene mutations among
the rifampicin-resistantMycobacterium tuberculosis (MTB) isolates from Pakistan. Rifampicin
mutation patterns were analyzed by using PCR followed by rpoB gene sequencing. Among
the 1080 referred TB cases, 63 (6%) were resistant against at least one first-line TB drug. Out
of these 63 resistant isolates, 24 isolates (38%) were found to be resistant to isoniazid and
rifampicin. Sequence analysis of multidrug-resistant tuberculosis (MDR-TB) isolates
detected a single mutation in the RRDR region of the rpoB gene at codon 531, 516, 512,
528 and 533; however, 5 MDR-TB isolates lack any mutation in the RRDR region. A double
mutation was observed in 1 MDR-TB isolate at codon 512 and 516 which are reported for
the first time from Pakistan. Moreover, in 1 isolate a novel silent mutation was observed
at codon 528. Further studies about these mutations may be helpful in the development
of diagnostic tools for the detection of MTB in a high TB endemic area like Pakistan.
 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.Introduction
Tuberculosis (TB) is one of the leading fatal diseases among
humans mostly caused by Mycobacterium tuberculosis (MTB).
It is estimated that one third of the world’s population is
latently infected with TB. Pakistan ranks fifth among the highTB burden countries in the world [1,2]. Antimicrobial therapy
is one of the effective strategies used to control TB. First-line
drugs, including rifampicin (RIF), isoniazid (INH), ethambutol,
pyrazinamide and streptomycin are the preferred choice for
TB control [3]. Recently, the emergence of multidrug-resistant
TB (MDR-TB) strains has become a serious public health
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consistently been contributing to increased annual TB inci-
dence rates [4–6]. MDR-MTB strains are resistant to RIF and
INH and thus limit the use of these available drugs [3].
RIF is an effective drug against MTB [7] which interferes
with transcription by the DNA-dependent RNA polymerase
[4]. In most cases, resistance to RIF is linked with mutations
within 81 bp hypervariable or hot spot regions of RIF resistance
determining region (RRDR) of the rpoB gene [4]. Detection of
rpoB gene mutations is considered a surrogative marker for
MDR-TB detection and can be used as a tool in MDR-TB diag-
nostics [8–11].
The patterns and frequency of mutations in the RRDR
region of the rpoB gene in the MTB clinical isolates vary signif-
icantly according to the geographical location [12]. Limited
data is available regarding the pattern of rpoB mutation in
the MDR-TB patients in Pakistan [13,14].
In the present study, PCR-based molecular detection of
rpoB gene mutations followed by DNA sequencing was per-
formed. Findings from the present study might be helpful in
the development of diagnostic tools for the rapid detection
of MDR-TB.
Materials and methods
Sample collection
A total of 1080 suspected TB referred cases from TB centers
and hospitals of Punjab were included in the study. The study
was conducted at the Bacteriology Laboratory, Institute of
Public Health, Lahore. The study was approved by the institu-
tional research ethical committee. Sputum samples from
these patients were collected in designated sterile bottles
and processed immediately.
Sputum smear microscopy, and In vitro drug susceptibility
testing (DST)
Sputum smears were Ziehl–Neelsen (ZN) stained and acid fast
bacilli (AFB) were examined under a bright field microscope.
Parallel to microscopy, all the collected sputum samples were
also processed for in vitro drug susceptibility testing. Sputum
samples were decontaminated using N-acetyl L-cysteine and
neutralized with sodium hydroxide [15]. MTB isolates were
cultured on a Lowenstein–Jensen (LJ) slant followed by incu-
bation at 37 C for at least 6–8 weeks. MTB colonies were iden-
tified by the para-nitrobenzoic acid (PNB) test and the nitrate
reductase test (NRT). Confirmed MTB isolates were tested for
in vitro drug sensitivity testing for RIF, INH and ethambutol
using the standard LJ proportion method as described earlier
[15,16]. Isolates were tested for resistance to RIF, INH and eth-
ambutol using concentrations of 40 lg/ml for RIF, 0.2 lg/ml for
INH and 2.0 lg/ml for ethambutol. Briefly, the diluted suspen-
sion of isolates were inoculated onto LJ medium with and
without drugs and incubated at 37 C. Results were read up
to 42 days of incubation. An isolate was considered resistant
to a given drug when growth of 1% or more as compared with
the control was observed in drug-containing medium. MTB
H37Rv wild type strain (ATCC 27294) was used as a control
for drug susceptibility testing [16,17].DNA extraction and molecular detection of MTB
Chromosomal DNA from MDR-MTB colonies was extracted
using QIAamp DNA Mini Kit (QIAGEN, Toronto, Canada). The
polymerase chain reaction (PCR) based amplification of rpoB
gene of MTB was achieved as described earlier by using 5 0-
GAGGCGATCACACCGCAGACGT-3 0 and 5 0-GATGTTGGGCCCCT
CAGGGGTT-30 as forward primer (RP4T) and reverse primer
(RP8T), respectively [18]. The amplified product was separated
on 1.5% agarose gel and ethidium bromide stained followed
by visualization under ultraviolet light in a gel documentation
system.
rpoB gene sequencing
The PCR product was processed for the DNA sequencing from
both ends using BigDye terminator cycle sequencing kit on
ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City,
USA). Bioinformatics analysis was done using ClustalW
(http://embnet.vital-it.ch/software/ClustalW.html) and NCBI
BLAST (http://www.ncbi.nlm.nih.gov/BLAST). DNA sequences
were translated to amino acid sequences using ExPASy trans-
late tool (http://web.expasy.org/translate/). The obtained
sequence data was compared with the reference sequence
of rpoB gene of MTB H37Rv.
Results
Susceptibility patterns of first-line TB drugs
Among the 1080 samples, 63 (6%) were resistant to at least
one TB drug. Out of these 63 resistant isolates, 24 isolates
(38%) were found to be resistant against INH and RIF. Among
24 MDR-TB cases, 53% were male while 47% were female
patients.Profile of rpoB gene mutations in MDR-TB isolates
Amplification of the 157 bp RRDR region of rpoB gene was
achieved and processed for DNA sequence analysis (Fig. 1).
rpoB gene mutations were detected in 19 out of 24 (79%) iso-
lates when compared with rpoB gene sequence of the refer-
ence strain. Out of 19, 11 (58%) isolates showed a mutation
at codon 531(TCG to TTG), 4 (21%) isolates exhibited a muta-
tion at codon 516 (GAC to GTC, GAC to TAC), 2 (11%) MDR-
TB isolates showed a mutation in the amino acid codon 512
(AGC to ATC) while 1 (5%) isolate showed a mutation at the
codon 533 (CTG to CCG); 1 (5%) isolate exhibited a silent muta-
tion at the codon 528 (CGC to CGT) (Table 1).Discussion
Drug resistance mostly develops by mutational interplay
rather than acquisition of resistant genes transfer from other
bacteria. Drug resistance in MTB isolates has widely been
investigated and is generally thought to be caused by sponta-
neous mutations [3,5,19]. Emergence of MDR-TB is a serious
challenge for clinicians; it arises mostly due to rpoB gene
mutations [20]. The frequency of mutations in MTB rpoB gene
Fig. 1 – PCR amplification of rpoB gene of phenotypic MDR-TB isolates. PCR product of rpoB was resolved on 1.5% agarose gel.
Lane (L) in the figure presents the 100 bp molecular weight DNA ladder. Lane S1 to S24 shows the amplification of 157 bp
region of rpoB gene from 24 phenotypic MDR-TB isolates.
Table 1 – Resistance conferring mutations in MDR-TB isolates.
Codon/nucleotide
change
Amino acid
change
Sample ID. No. of
Isolates
Rate of
mutations (%)
Selected
references
TCG! TTG S531L 1, 2, 3, 4, 9, 12, 14, 16, 17, 20, 22 11 58 [13,23]
GAC! GTC D516V 5, 13, 15 3 16 [17]
GAC! TAC D516Y 18 1 5 [17]
AGC! ATC S512I 18, 21 2 11 [24] and In this study
CGC! CGT R528R 10 1 5 In this study
CTG! CCG L533P 24 1 5 [25]
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reported earlier in Asian countries, which are generally asso-
ciated with a high-level of resistance to RIF [21]. Despite Paki-
stan being a highly TB endemic area, few studies are available
regarding molecular characterization of rpoB mutations in
MDR-TB patients [13,14,17]. The information regarding the
prevalence of these mutations might be helpful for better
therapy and management of MDR-TB patients.
In the current study, a total of 1080 referred TB cases were
processed for first-line drug susceptibility testing; 63 out of
1080 (6%) isolates were resistant against one first-line TB drug.
Out of these 63 resistant isolates, 24 isolates (38%) were found
to be resistant against isoniazid and rifampicin. Among 24
MDR-TB cases, 53% were male while 47% were female
patients, which is in agreement with the previous study [22].
Genotypic analysis was only done for MDR-TB isolates (24
cases) by PCR amplification of 157 bp rpoB gene. DNA
sequencing of the purified PCR product from all the MDR-TB
isolates were accomplished in order to identify mutations in
the RRDR region of the rpoB gene. DNA sequence data was
compared with the sequence of rpoB gene of the wild type
MTB strain. Sequencing results showing a mutation in the 157bp
region of rpoB in 19 RIF-resistant isolates out of 24 MDR-TB iso-lates (79%), reflects the importance of detection of rpoB gene
mutations as a tool in MDR-TB diagnostics [11]. Out of 19 iso-
lates, 58% of the total MDR-TB isolates showed a mutation at
codon 531 (TCG to TTG) that resulted in a change of serine to
leucine; these findings are in line with an earlier study which
reported codon 531 as a hot spot for rpoB gene mutations in
MTB [23]. A previous study on MDR-TB isolates from Punjab,
Pakistan has reported a 52% prevalence rate of rpoB mutation
at amino acid codon 531 [13]; 21% of isolates inhabited the
mutation in codon 516 (GAC to GTC, GAC to TAC) that resulted
in the conversion of two amino acids (aspartate to valine and
tyrosine, respectively), which is in line with a previous work
which documented a 24% mutation rate at codon 516 [17].
Among MDR-TB isolates, 11% of isolates showed a mutation
at codon 512 (AGC to ATC) which replaced serine with isoleu-
cine. This point mutation (AGC to ATC) at codon 512 is
observed for the first time only in Pakistani MDR-TB isolates,
which may be an addition to a succession of reported muta-
tions; however, a similar point mutation was observed in a
study from Poland [24]; 5% of the isolates showed a mutation
at codon 533 (CTG to CCG) that shifted leucine with proline as
reported in a study from Turkey [25]. In 5% of the isolates a
novel silent mutation was observed at codon 528 (CGC to
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reported even globally. Silent mutations on other codons were
reported by Isfahani et al. [26]. A double mutation was
observed in one MDR-TB isolate at codon 512 and 516. Similar
mutations were also documented earlier [4,27].
Five (20%) MDR-TB isolates lack any mutation in the RRDR
region of the rpoB gene, though these isolates were phenotyp-
ically resistant to RIF. This difference might persist due to
genotype variations prevailing worldwide; however, the pres-
ence of mutations in the rpoB gene other than the RRDR
region could not be excluded as described by Heep et al.
[28]. Lack of RRDR mutations in resistant isolates might be
due to the presence of other rare rpoB mutations or another
mechanism of resistance to rifampicin [13,28]. These findings
are consistent with previous reports from several countries
[13,20,23,28,29].
The frequencies and distribution of mutations at RRDR loci
in drug-resistant MTB from Pakistan were investigated. The
patterns of mutation in this study coincide with that of the
majority of MTB isolates prevalent globally. Further study
concerning these mutations might be helpful in the develop-
ment of diagnostic tools for the rapid detection of MTB.
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